Joint (NASDAQ:JYNT) Stock Rating Reaffirmed by Roth Mkm

Joint (NASDAQ:JYNT)‘s stock had its “buy” rating reissued by equities research analysts at Roth Mkm in a research note issued to investors on Friday, Benzinga reports. They currently have a $16.00 target price on the stock, up from their prior target price of $13.00. Roth Mkm’s price target points to a potential downside of 0.74% from the company’s current price.

Separately, TheStreet downgraded Joint from a “c-” rating to a “d” rating in a research note on Thursday, March 7th. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Joint Stock Performance

Shares of JYNT stock opened at $16.12 on Friday. The company’s fifty day moving average price is $12.05 and its 200-day moving average price is $10.15. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.32 and a current ratio of 1.32. Joint has a 12 month low of $7.31 and a 12 month high of $16.43.

Joint (NASDAQ:JYNT) last issued its quarterly earnings results on Thursday, March 7th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The company had revenue of $30.61 million during the quarter, compared to analysts’ expectations of $29.63 million. Joint had a negative net margin of 9.24% and a positive return on equity of 3.76%. Equities analysts expect that Joint will post 0.13 earnings per share for the current year.

Institutional Trading of Joint

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP grew its holdings in shares of Joint by 345.0% during the third quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock valued at $37,000 after buying an additional 3,233 shares during the last quarter. Barclays PLC lifted its position in Joint by 29.4% in the 3rd quarter. Barclays PLC now owns 13,725 shares of the company’s stock valued at $123,000 after acquiring an additional 3,119 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Joint by 43.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,506 shares of the company’s stock valued at $148,000 after purchasing an additional 4,987 shares during the last quarter. Avondale Wealth Management increased its holdings in shares of Joint by 192.3% in the 1st quarter. Avondale Wealth Management now owns 19,000 shares of the company’s stock worth $248,000 after purchasing an additional 12,500 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in shares of Joint in the third quarter worth $179,000. 76.88% of the stock is currently owned by institutional investors.

About Joint

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.